Big Pharma Cares: Carsten Thiel’s Philanthropic and Ethical Contributions
( Newswire.net — November 19, 2019) — As a multi-disciplinary leader in the realm of biopharmacology with over twenty five years of pertinent experience within the continuously growing field, Carsten Thiel has bore witness to the continuous evolutions of the discipline. With evolving technological advancements, burgeoning new treatment options, and cultural shifts in general opinions about the medical industry, the pharmaceutical industry has ebbed and flowed to actively embrace these changes. Actively and consistently engaged in the continuous changes that have led to the betterment of the industry, Carsten Thiel has recognized the merit of acting in an ethical manner at all times, and maintaining a patient first approach, despite potential financial detriment. While the pharmaceutical industry is comprised of many leading for-profit companies, Thiel purports that the entire purpose for the existence of these companies is to serve, aid, and heal various individuals suffering from multiple medical conditions. For Thiel, this consideration has been a driving force throughout his career, and has resulted in his participation in various charitable efforts, championing of patient successes, and desire to truly impact the lives of all individuals.
Unwilling to commit to the status quo, Thiel spearheaded marketing efforts for the product that provided honest expectations, transparency in terms of the need to maintain healthy lifestyle choices in tandem with the medication, and targeting of selective individuals who would most benefit from the medication. With this patient-first approach, Thiel argued mutually beneficial results, where smaller numbers of highly satisfied customers would not only provide adequate sales numbers, but would spread the news of efficacy, bolstering sales on a long-term basis, and building the entire brand’s positive reputation, a feat intrinsically worth more than high first-year sales figures. In pursuing this approach, young Thiel was met with some skepticism from traditional peers, but his convictions regarding ethics, and the patient-first approach, bolstered Thiel’s desire to forge ahead with his ethically based marketing efforts. Through his approach, the launch of Xenical was met with extremely positive consumer reviews and opinions, and first-year sales of the drug reached in excess of 1 billion Swiss francs, a considerable success across all considerations.
For Thiel, a primarily ethically driven motivation continues to be the eradication of various conditions, ailments, and diseases. With an innate and intrinsic desire to truly help people, Thiel continues to be enthralled by the implementation of technological advancements within the realm of medicine, and the transformative power of these advancements throughout what he refers to as The Golden Age Of Medicine, and beyond. According to Thiel, the biopharmaceutical field has been able to implement numerous life-saving advancements within the previous few years, including the development of effective treatment for previously lifelong Hepatitis C, the initial creation of DNA changing treatment for eye diseases, and other forward-thinking advancements.
Through his latest assignment as President Europe of EUSA Pharma , Thiel hopes to leverage his extensive previous experiences to spearhead the continued development of treatment options for numerous underserved populations. Tasked with growing the company’s European infrastructure to support ongoing growth, Thiel’s assignment fits his lifelong mission of ethical contributions to the medical field, and his desire to create systemic change for affected individuals. Founded in March of 2015, EUSA’s mission statement focuses on transformative care in the niche realm of Oncology, and rare diseases. Since the company’s inception, EUSA has garnered immediate success, and has developed several effective treatments at a staggering pace. With continued growth and expansion, Thiel will parlay his previously perfected skill sets, in tandem with his intrinsic beliefs, to create the infrastructure needed to adequately support ongoing growth, and to ensure the company’s continued foray as an industry leader in the care of rare diseases. For Thiel, this meaningful assignment is a continuation of his previous roles, in a capacity that allows him to effectively spearhead ethical practices and breakthrough developments in the pharmaceutical industry, a continued professional motivator for the industry veteran.
Additionally, Carsten has sponsored a local school in Kenya, which has allowed the implementation of infrastructure needed to support growth. Growing from supporting only 50 kids in 2014, to now shaping the future for over 400 students, the school acts as a beacon for opening the doors to expanded career opportunities for these children in the future. Located between Kenya and Tanzania, the school stands alone as the singular educational center in the region, with many children traveling by foot in excess of one hour to receive high-quality education. Without Thiel’s exceptional support, the school would not have been able to support additional students, offering opportunities for self-betterment, and increased career trajectories to otherwise traditionally limited populations. Understanding the tremendous impact of his support, Thiel considers this philanthropic venture to be vastly meaningful, and relishes knowing that he has been able to create a direct and positive effect in the lives of others.
Originally published at https://newswire.net on November 19, 2019.
